RxDoctor Payments Data

Molly Ware, MD

Cardiovascular Disease · Boulder, CONPI 1700863545

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $17,500 of the $21,265 with a category attached, or 82.3%. Boston Scientific accounts for 94.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $10,961 and has fallen 52.1% since, to $5,246 in 2025. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,265in general payments, 2019–2025

Across 52 payments — averaging $408.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$20K
  • Abbott$811
  • Heartflow, Inc.$158
  • Medtronic$124
  • Biosense Webster, Inc.$33
  • Edwards Lifesciences$29
  • plus $14 from 1 others

What the payments were for

  • Speaking & faculty fees$17,50082%
  • Travel & lodging$2,61112%
  • Food & beverage$1,1545%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,265 in reported general payments places this provider in the 90th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$141,351
Medicare patients
926
Services billed
2,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban256$376,072
Repatha SureclickEvolocumab43$43,318
JardianceEmpagliflozin27$38,587
XareltoRivaroxaban16$18,916
Praluent PenAlirocumab11$14,388
Metoprolol Succinate331$4,320
Atorvastatin Calcium390$3,845
Nebivolol Hcl46$3,626
Rosuvastatin Calcium323$3,306
Losartan Potassium342$2,611
Ezetimibe71$2,264
Amlodipine Besylate199$1,372
InvokanaCanagliflozin12$1,198
Diltiazem 24hr Er (Cd)Diltiazem Hcl30$1,195
Carvedilol107$966

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Boulder

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →